T1	Participants 352 486	patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. Patients
T2	Participants 868 966	1,253 patients with metastatic NSCLC previously treated with a platinum-based combination therapy.
T3	Participants 1933 1941	patients